9th Annual Biomarkers Congress

Cancer Biology: Bristol-Myers Squibb

Total Score People Score Events Score
29 23 24
Date Event Presentation Speakers
May 23, 2012 Biomarkers World Europe 2012 Integrating technologies in targeted medicine biomarker strategies Michael Burczynski
November 12, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Development of ipilimumab (anti-CTLA-4) and beyond: Contribution to a new immunotherapy paradigm Axel Hoos
April 11, 2011 Personalized Medicine Partnerships Conference Rx/Dx Partnering | Two Products Towards One Goal | Delivering the Prospect of Personalized Medicine Andrea H. Lauber
August 25, 2010 Co-Development of Drugs and Diagnostics Challenges of Co-Development of Therapeutics and Companion Diagnostics Andrea H. Lauber
July 7, 2010 WIN Symposium in personalized cancer medicine Phase II and III clinical trial design and endpoints in targeted therapy era-future goals and challenges. Giuseppe Giaccone
April 27, 2010 Anti-inflammatories: Small Molecule Approaches Optimization of a Series of Tricyclic Inhibitors of 1 Kappa B Kinase Inhibitors and Efficacy in Chronic Murine Models of Arthritis William Pitts
April 6, 2010 IBCs 5th Annual China 2010 Pharmaceutical R&D Summit 1 Key Factors to be Considered for Clinical Development in Emerging Markets Ruiping Dong
1 Chairperson's Opening Remarks Ruiping Dong
September 23, 2009 Track 3: Advancing Cancer Therapy : Second Annual Translational Cancer Medicine Combination Approaches for the Treatment of Solid Tumors: Opportunities and Obstacles in the Era of Targeted Therapy Jon M Wigginton
June 9, 2009 RNAi for Target Identification and Validation Use of RNAi Screens with Physiologically Relevant Cell Models to Identify Novel Therapeutic Targets Namjin Chung
June 8, 2009 Tackling RNAi Delivery OPTIMIZING RNAi DELIVERY FOR IN VITRO APPLICATIONS Namjin Chung
April 7, 2009 Kinase Inhibitor Chemistry - Charting the Chemical Space Binding Modes of Fragment-Like Kinase Inhibitors Keith Constantine
November 4, 2008 The Chemotherapy Foundation Symposium XXVI OR Chemotherapy Foundation Symposium, Innovative Cancer Therapy for Tomorrow TALACTOFERRIN IN REFRACTORY NSCLC Giuseppe Giaccone
October 21, 2008 Kinase Inhibitors Dissecting Kinase Inhibitor Activities by Genome-Wide Dose Response Analysis Rui-Ru Ji
Talk Title to Be Announced John Hynes
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Integrating ‘omics’ technologies into Safety Evaluation and Risk Assessment Lois-Lehman McKeeman
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Faculty Renzo Canetta, Giuseppe Giaccone, Ashok Batra
Panelists Renzo Canetta
May 30, 2008 ASCO Annual'08 Meeting clinical trials-- Choice of Comparator in Pivotal Phase III Clinical Trials: Clinical Versus Regulatory Standard of Care Steven D. Averbuch
clinical trials-- Endpoints for Immunotherapy Studies: Design and Regulatory Implications Axel Hoos
international-- Choice of Comparator in Pivotal Phase III Clinical Trials: Clinical Versus Regulatory Standard of Care Steven D. Averbuch
tumor biology-- Endpoints for Immunotherapy Studies: Design and Regulatory Implications Axel Hoos
March 25, 2008 Molecular Diagnostics Affordability Through Sustainability – A New Approach to Technology Innovation Balu Balasubramanian
March 25, 2008 R&D Risk Mitigation Alliance Management: How Can Large and Small Companies Work Together? Teresa Faria
December 1, 2007 47TH American Socieity of Cell Biology Post-Cytokinetic DNA Segregation by ATPases That Form DNA-Conducting Channels Lois Burton
November 15, 2007 The Joint Meeting of the 4th ISC International Conference on Cancer Therapeutics and The 7th Princess Margaret Hospital Conference: New Developments in Cancer Management Session II: Lung Cancer Giuseppe Giaccone
Surgical debate: Is there a role for surgery in stage IIIA NSCLC? Giuseppe Giaccone
November 15, 2007 Second Annual Drug Development India : Planning and Managing Drug Discovery & Development Activities Nov(15-16) PRECLINICAL DEVELOPMENT AND CHALLENGES (15:30-18:45) Pankaj Shah
PRECLINICAL DEVELOPMENT AND CHALLENGES: INTERACTIVE PANEL :Partnership and Outsourcing Deals in India – Successes and Failures (17:00-17:45) Pankaj Shah
October 17, 2007 Inaugral Nuclear Harmone Receptors Modulators: Targets for Drug Discovery Oct (17-18) DISCOVERY CHEMISTRY (08:35-12:55) Lawrence G. Hamann
DISCOVERY CHEMISTRY: Tissue Selective Androgen Receptor Modulators (11:25-11:55) Lawrence G. Hamann
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) RNAi FOR IN VIVO TARGET VALIDATION: Validation of Drug Targets Through in vivo Application of siRNA Oligonucleotides (16:30-17:00) Siew Ho
RNAi FOR IN VIVO TARGET VALIDATION (16:30-19:30) Siew Ho
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third annual Genomic Biomarkers: PHARMACOGENETICS: Changing the Benefit/Risk Profile Using Pharmacogenetics (09:05-09:35) Koustubh Ranade
Third annual Genomic Biomarkers: PHARMACOGENETICS (08:30-11:30) Koustubh Ranade
Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS: Discovery and Validation of Biomarkers Affected by Brivanib and Erbitux (11:30-12:00) J. Suso Platero
Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS (11:30-14:00) J. Suso Platero
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.